Although the four-week long treatment with QHD or GC did not impact body (Figure 1A) and liver weight (Figure 1B) of NAFLD rats, both treatments decreased liver TG (Figure 1C), serum ALT (Figure 1D) and AST (Figure 1E) to similar levels as control rats. Here, GPT is linked to metabolic dysfunction-associated steatotic liver disease.